Y-mAbs Therapeutics (YMAB) - Long-Term Debt to Capital

Corporate emblem and logo of Y-mAbs Therapeutics (YMAB)

The current market quotes for Y-mAbs Therapeutics (YMAB) visualized below on GURU.Markets reflect the price action of a company that adheres to bioethics in pediatric testing and environmental standards for waste disposal. The business is actively scaling its commercial reach by expanding its pipeline of treatments for pediatric tumors. Yields reaching 0.03 are supported by the commercialization of radio-immunotherapeutic antibodies and milestone payments from partners for research success.

YmAbs - YMAB Long-Term Debt to Capital (period 07/04/2022 - 09/27/2025)

Analytical breakdowns for Y-mAbs Therapeutics

- stock value and consensus price forecast:
Stock Quotes Y-mAbs Therapeutics Inc|YMAB - Analyst Consensus Forecast
- market capitalization indicators:
Market Capitalization Y-mAbs Therapeutics, Inc.|YMAB - Total Company Value
- company book value details:
Equity per Share Y-mAbs Therapeutics|YMAB - Book Capitalization|Market Cap to Net Assets Ratio ymabs.com|YMAB - Company Total Assets
- company liabilities and liquidity data:
Debt to Capital Y-mAbs Therapeutics|YMAB - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital ymabs.com|YMAB - Company Total Debt|Debt to Net Assets Ratio Y-mAbs Therapeutics, Inc.|YMAB - Company Long-Term Debts|Company Current Liabilities Y-mAbs Therapeutics|Quick Ratio ymabs.com
- financial results and valuation multiples details:
YMAB - Company Net Income
General company analysis:Y-mAbs Therapeutics Inc - YMAB
Original product of ymabs.com

This indicator determines the issuer's long-term solvency by comparing liabilities with maturities exceeding one year against the size of total equity. By analyzing the long-term debt-to-equity chart, an investor assesses default risk against expansion potential, which is critical for the research-intensive business of Y-mAbs Therapeutics (YMAB) when financing costly developments in pediatric oncology and retaining rare specialists through grants.

Key competitors

Long-Term Debt to Equity Ratio BeiGene Ltd. (ONC)|Long-Term Debt to Capital HALO|Long-Term Debt to Capital Revolution Medicines Corp (RVMD)|Long-Term Debt to Equity Ascentage Pharma Group AAPG|CGON: Long-Term Debt to Capital Ratio|UroGen Pharma - Long-Term Debt to Capital|Bicara Therapeutics Inc (BCAX) - Long-Term Debt to Equity Ratio|PSNL: Long-Term Debt to Capital|Long-Term Liabilities to Capital Erasca Oncology (ERAS)|Long-Term Debt to Equity Delcath Systems, Inc.|AURA: Long-Term Debt to Capital Coefficient|Long-Term Debt to Equity Ratio CADL (Candel Therapeutics)|ARAY (Accuray Inc) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital SLS (SELLAS Life Sciences Group)|ACTU - Long-Term Debt to Equity Ratio|CTOR: Long-Term Debt to Equity Ratio|HURA - Long-Term Debt to Capital|Protara Therapeutics, Inc. (TARA) - Long-Term Debt to Equity|Fate Therapeutics Inc - Long-Term Debt to Capital Coefficient|WHWK (Aadi Bioscience, Inc.) - Long-Term Debt to Capital|Long-Term Liabilities to Capital TScan TCRX|Long-Term Debt to Equity Ratio CSBR (Champions Oncology)|XBIT - Long-Term Liabilities to Capital|CEL-SCI - Long-Term Debt to Equity Ratio|Long-Term Indebtedness to Equity OS Therapies Inc.|RADX - Long-Term Debt to Equity|Artiva Biotherapeutics, Inc. (ARTV) - Long-Term Debt to Equity Ratio|ANL: Long-Term Debt to Capital|verupharma.com (VERU) - Long-Term Debt to Capital|TPST (Tempest Therapeutics, Inc.) - Long-Term Debt to Capital|Long-Term Debt to Equity XLO|Long-Term Debt to Equity Renovaro Inc. (RENB)|Ratio of Long-Term Indebtedness to Capital muraloncology.com|Kairos Pharma - Long-Term Debt to Equity Ratio|Long-Term Debt to Capital Coefficient OKUR|GDTC: Long-Term Debt to Equity Ratio|Curis, Inc. - Long-Term Loans to Capital Ratio|APLM: Long-Term Debt to Capital|Tharimmune Corporation - Long-Term Debt to Capital Coefficient|ADVB (Advanced Biomed Inc.) - Long-Term Debt to Capital|Long-Term Liabilities to Capital genprex.com GNPX|Long-Term Debt to Equity Calidi Biotherapeutics (CLDI)|SBFM (Sunshine Biopharma Inc.) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital XBIO (Xenetic Biosciences, Inc.)|Long-Term Debt to Capital Salarius Pharma SLRX|PPBT - Long-Term Debt to Equity|Long-Term Liabilities to Equity AONC|BGNE: Long-Term Debt to Capital|Long-Term Liabilities to Capital Checkpoint Therapeutics Inc. (CKPT)|Long-Term Debt to Equity Ratio ELEV|Long-Term Debt to Capital iCAD Corp|Long-Term Debt to Equity Ratio IKNA (Ikena Oncology, Inc.)|Long-Term Loans to Capital Ratio NTBL|Long-Term Debt to Capital VIRX (Viracta Therapeutics, Inc.)|Ratio of Long-Term Indebtedness to Capital MorphoSys Inc (MOR)|NAYA Bio - Long-Term Debt to Capital|Ascentage (AAPGV) - Long-Term Debt to Equity Ratio